Lupin yesterday announced that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Pregabalin capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg to market a generic equivalent of Lyrica capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg of Upjohn US 2 LLC.
The product will be manufactured at Lupin’s facility in Aurangabad, the company said in a statement.